Jim Wilson (WuXi Global Forum at JPM20)
March 15, 2022 09:12 AM EDTUpdated March 18, 01:39 PM
People
R&D

Roiled by se­nior-lev­el ex­its, Jim Wil­son’s Pas­sage Bio re­trench­es, chop­ping back on staff as it ex­tends cash run­way

John Carroll

Editor & Founder

A lit­tle more than 3 years af­ter Penn’s Jim Wil­son and the late Tachi Ya­ma­da her­ald­ed the launch of their gene ther­a­py up­start Pas­sage …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times